This company has been marked as potentially delisted and may not be actively trading.

Enfusion (ENFN) Competitors

ENFN vs. PATH, PCTY, GLBE, OTEX, and PSN

Should you be buying Enfusion stock or one of its competitors? The main competitors of Enfusion include UiPath (PATH), Paylocity (PCTY), Global-e Online (GLBE), Open Text (OTEX), and Parsons (PSN). These companies are all part of the "computer software" industry.

How does Enfusion compare to UiPath?

Enfusion (NYSE:ENFN) and UiPath (NYSE:PATH) are both computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

: 81.1% of Enfusion shares are owned by institutional investors. Comparatively, 62.5% of UiPath shares are owned by institutional investors. 36.4% of Enfusion shares are owned by company insiders. Comparatively, 23.2% of UiPath shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: In the previous week, UiPath had 19 more articles in the media than Enfusion. MarketBeat recorded 19 mentions for UiPath and 0 mentions for Enfusion. UiPath's average media sentiment score of 0.56 beat Enfusion's score of 0.00 indicating that UiPath is being referred to more favorably in the news media.
Company Overall Sentiment
Enfusion Neutral
UiPath Positive
: UiPath has a consensus target price of $14.07, suggesting a potential upside of 28.87%. Given UiPath's stronger consensus rating and higher probable upside, analysts plainly believe UiPath is more favorable than Enfusion.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enfusion
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
UiPath
1 Sell rating(s)

14 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.11
: Enfusion has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, UiPath has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.
: UiPath has a net margin of 17.53% compared to Enfusion's net margin of 1.70%. Enfusion's return on equity of 6.67% beat UiPath's return on equity.
Company Net Margins Return on Equity Return on Assets
Enfusion 1.70% 6.67% 4.86%
UiPath 17.53% 5.69% 3.71%
: UiPath has higher revenue and earnings than Enfusion. UiPath is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Enfusion $201.61M 6.88 $6.03M $0.03 358.67
UiPath $1.61B 3.55 $282.33M $0.52 20.99

Company	Overall Sentiment
Enfusion	Neutral
UiPath	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enfusion	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
UiPath	1 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11

Company	Net Margins	Return on Equity	Return on Assets
Enfusion	1.70%	6.67%	4.86%
UiPath	17.53%	5.69%	3.71%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enfusion	$201.61M	6.88	$6.03M	$0.03	358.67
UiPath	$1.61B	3.55	$282.33M	$0.52	20.99

Summary

UiPath beats Enfusion on 9 of the 16 factors compared between the two stocks.

How does Enfusion compare to Paylocity?

Paylocity (NASDAQ:PCTY) and Enfusion (NYSE:ENFN) are both computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

: 94.8% of Paylocity shares are owned by institutional investors. Comparatively, 81.1% of Enfusion shares are owned by institutional investors. 19.4% of Paylocity shares are owned by company insiders. Comparatively, 36.4% of Enfusion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Paylocity has a net margin of 14.19% compared to Enfusion's net margin of 1.70%. Paylocity's return on equity of 23.44% beat Enfusion's return on equity.
Company Net Margins Return on Equity Return on Assets
Paylocity 14.19% 23.44% 5.24%
Enfusion 1.70% 6.67% 4.86%
: Paylocity has higher revenue and earnings than Enfusion. Paylocity is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Paylocity $1.60B 3.69 $227.13M $4.25 25.68
Enfusion $201.61M 6.88 $6.03M $0.03 358.67
: In the previous week, Paylocity had 16 more articles in the media than Enfusion. MarketBeat recorded 16 mentions for Paylocity and 0 mentions for Enfusion. Paylocity's average media sentiment score of 1.08 beat Enfusion's score of 0.00 indicating that Paylocity is being referred to more favorably in the media.
Company Overall Sentiment
Paylocity Positive
Enfusion Neutral
: Paylocity has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, Enfusion has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.
: Paylocity presently has a consensus price target of $172.72, suggesting a potential upside of 58.29%. Given Paylocity's stronger consensus rating and higher probable upside, analysts clearly believe Paylocity is more favorable than Enfusion.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Paylocity
1 Sell rating(s)
4 Hold rating(s)

14 Buy rating(s)

0 Strong Buy rating(s)
2.68
Enfusion
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Net Margins	Return on Equity	Return on Assets
Paylocity	14.19%	23.44%	5.24%
Enfusion	1.70%	6.67%	4.86%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Paylocity	$1.60B	3.69	$227.13M	$4.25	25.68
Enfusion	$201.61M	6.88	$6.03M	$0.03	358.67

Company	Overall Sentiment
Paylocity	Positive
Enfusion	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Paylocity	1 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.68
Enfusion	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Paylocity beats Enfusion on 12 of the 16 factors compared between the two stocks.

How does Enfusion compare to Global-e Online?

Enfusion (NYSE:ENFN) and Global-e Online (NASDAQ:GLBE) are both computer software companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

: Global-e Online has higher revenue and earnings than Enfusion. Global-e Online is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Enfusion $201.61M 6.88 $6.03M $0.03 358.67
Global-e Online $962.20M 5.76 $68.27M $0.37 88.19
: Global-e Online has a net margin of 7.10% compared to Enfusion's net margin of 1.70%. Global-e Online's return on equity of 7.46% beat Enfusion's return on equity.
Company Net Margins Return on Equity Return on Assets
Enfusion 1.70% 6.67% 4.86%
Global-e Online 7.10% 7.46% 5.31%
: 81.1% of Enfusion shares are held by institutional investors. Comparatively, 94.6% of Global-e Online shares are held by institutional investors. 36.4% of Enfusion shares are held by insiders. Comparatively, 11.6% of Global-e Online shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: Global-e Online has a consensus price target of $46.77, suggesting a potential upside of 43.33%. Given Global-e Online's stronger consensus rating and higher possible upside, analysts clearly believe Global-e Online is more favorable than Enfusion.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enfusion
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Global-e Online
0 Sell rating(s)

2 Hold rating(s)

11 Buy rating(s)

2 Strong Buy rating(s)
3.00
: Enfusion has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Global-e Online has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.
: In the previous week, Global-e Online had 11 more articles in the media than Enfusion. MarketBeat recorded 11 mentions for Global-e Online and 0 mentions for Enfusion. Global-e Online's average media sentiment score of 0.43 beat Enfusion's score of 0.00 indicating that Global-e Online is being referred to more favorably in the news media.
Company Overall Sentiment
Enfusion Neutral
Global-e Online Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enfusion	$201.61M	6.88	$6.03M	$0.03	358.67
Global-e Online	$962.20M	5.76	$68.27M	$0.37	88.19

Company	Net Margins	Return on Equity	Return on Assets
Enfusion	1.70%	6.67%	4.86%
Global-e Online	7.10%	7.46%	5.31%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enfusion	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Global-e Online	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Company	Overall Sentiment
Enfusion	Neutral
Global-e Online	Neutral

Summary

Global-e Online beats Enfusion on 14 of the 17 factors compared between the two stocks.

How does Enfusion compare to Open Text?

Enfusion (NYSE:ENFN) and Open Text (NASDAQ:OTEX) are both computer and technology companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

: In the previous week, Open Text had 9 more articles in the media than Enfusion. MarketBeat recorded 9 mentions for Open Text and 0 mentions for Enfusion. Open Text's average media sentiment score of 1.38 beat Enfusion's score of 0.00 indicating that Open Text is being referred to more favorably in the news media.
Company Overall Sentiment
Enfusion Neutral
Open Text Positive
: Open Text has a net margin of 8.42% compared to Enfusion's net margin of 1.70%. Open Text's return on equity of 23.60% beat Enfusion's return on equity.
Company Net Margins Return on Equity Return on Assets
Enfusion 1.70% 6.67% 4.86%
Open Text 8.42% 23.60% 6.94%
: Open Text has higher revenue and earnings than Enfusion. Open Text is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Enfusion $201.61M 6.88 $6.03M $0.03 358.67
Open Text $5.17B 1.11 $435.87M $1.70 13.94
: Open Text has a consensus target price of $36.00, indicating a potential upside of 51.96%. Given Open Text's stronger consensus rating and higher possible upside, analysts plainly believe Open Text is more favorable than Enfusion.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enfusion
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Open Text
0 Sell rating(s)

10 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.23
: 81.1% of Enfusion shares are owned by institutional investors. Comparatively, 70.4% of Open Text shares are owned by institutional investors. 36.4% of Enfusion shares are owned by insiders. Comparatively, 10.6% of Open Text shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: Enfusion has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Open Text has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Company	Overall Sentiment
Enfusion	Neutral
Open Text	Positive

Company	Net Margins	Return on Equity	Return on Assets
Enfusion	1.70%	6.67%	4.86%
Open Text	8.42%	23.60%	6.94%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enfusion	$201.61M	6.88	$6.03M	$0.03	358.67
Open Text	$5.17B	1.11	$435.87M	$1.70	13.94

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enfusion	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Open Text	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

Summary

Open Text beats Enfusion on 12 of the 16 factors compared between the two stocks.

How does Enfusion compare to Parsons?

Parsons (NYSE:PSN) and Enfusion (NYSE:ENFN) are both computer software companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

: Parsons has higher revenue and earnings than Enfusion. Parsons is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Parsons $6.36B 0.86 $241.14M $2.09 24.53
Enfusion $201.61M 6.88 $6.03M $0.03 358.67
: Parsons has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Enfusion has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
: Parsons has a net margin of 3.62% compared to Enfusion's net margin of 1.70%. Parsons' return on equity of 11.52% beat Enfusion's return on equity.
Company Net Margins Return on Equity Return on Assets
Parsons 3.62% 11.52% 5.36%
Enfusion 1.70% 6.67% 4.86%
: Parsons presently has a consensus price target of $78.17, suggesting a potential upside of 52.48%. Given Parsons' stronger consensus rating and higher possible upside, equities research analysts plainly believe Parsons is more favorable than Enfusion.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Parsons
0 Sell rating(s)
6 Hold rating(s)

9 Buy rating(s)

0 Strong Buy rating(s)
2.60
Enfusion
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: In the previous week, Parsons had 16 more articles in the media than Enfusion. MarketBeat recorded 16 mentions for Parsons and 0 mentions for Enfusion. Parsons' average media sentiment score of 0.44 beat Enfusion's score of 0.00 indicating that Parsons is being referred to more favorably in the media.
Company Overall Sentiment
Parsons Neutral
Enfusion Neutral
: 98.0% of Parsons shares are owned by institutional investors. Comparatively, 81.1% of Enfusion shares are owned by institutional investors. 1.3% of Parsons shares are owned by company insiders. Comparatively, 36.4% of Enfusion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parsons	$6.36B	0.86	$241.14M	$2.09	24.53
Enfusion	$201.61M	6.88	$6.03M	$0.03	358.67

Company	Net Margins	Return on Equity	Return on Assets
Parsons	3.62%	11.52%	5.36%
Enfusion	1.70%	6.67%	4.86%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parsons	0 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.60
Enfusion	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
Parsons	Neutral
Enfusion	Neutral

Summary

Parsons beats Enfusion on 12 of the 16 factors compared between the two stocks.

Get Enfusion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENFN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENFN vs. The Competition

Export

Metric	Enfusion	Prepackaged software Industry	Computer Sector	NYSE Exchange
Market Cap	$1.39B	$8.01B	$38.55B	$23.23B
Dividend Yield	N/A	0.89%	3.16%	4.00%
P/E Ratio	269.07	34.01	164.61	28.31
Price / Sales	6.88	6.29	625.08	24.52
Price / Cash	78.75	35.49	46.83	25.54
Price / Book	17.64	11.47	9.43	4.67
Net Income	$6.03M	$83.56M	$1.03B	$1.07B

Enfusion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENFN Enfusion	N/A	$10.76 flat	N/A	N/A	$1.39B	$201.61M	269.07	890
PATH UiPath	4.5168 of 5 stars	$10.56 +1.0%	$14.07 +33.2%	-11.2%	$5.48B	$1.61B	20.31	3,981	Trending News Gap Up
PCTY Paylocity	4.2255 of 5 stars	$102.46 +1.1%	$177.21 +73.0%	-45.2%	$5.46B	$1.68B	24.11	6,700	News Coverage Positive News
GLBE Global-e Online	4.43 of 5 stars	$31.94 -0.7%	$46.77 +46.4%	-14.5%	$5.46B	$962.20M	86.32	1,219	News Coverage Upcoming Earnings Insider Trade
OTEX Open Text	4.8325 of 5 stars	$22.49 -0.1%	$35.33 +57.1%	-13.7%	$5.45B	$5.17B	13.23	21,400	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ENFN) was last updated on 5/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enfusion (ENFN) Competitors